Theratechnologies (TSX: TH) announced today its financial results for the third quarter ended August 31, 2006 and reviewed recent highlights.
"The announcement of our Phase 3 results for TH9507 which are expected towards the end of 2006 will be a major milestone for Theratechnologies," said Mr. Yves Rosconi, President and Chief Executive Officer. "During the quarter, we made significant progress in our Phase 3 clinical program, notably with the special protocol assessment received from the Food and Drug Administration (FDA). In addition, we worked diligently in order to lay the groundwork for the second Phase 3 which is slated to begin in early 2007. These efforts and our sound financial position should enable us to achieve our objectives for the year," he added.
